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Abstract  
The prognosis of patients with gastric carcinomas at an advanced stage still 
remains dismal and therefore novel therapeutic modalities are urgently needed. 
Since the successful targeting of amplified ERBB2 with a humanized monoclonal 
antibody, the amplified genes of other receptor tyrosine kinases such as EGFR, 
FGFR2 and MET, as well as those of other cell regulator genes, are being 
considered as candidate targets of molecular therapy. The aim of the present study 
was to determine the amplification status of 26 genes, which are frequently 
amplified in solid cancers, in advanced gastric cancers. A total of 93 
formalin-fixed and paraffin-embedded advanced gastric cancer tissues were 
examined by multiple ligation-dependent probe amplification, and 32 cases with 
‘gain’ or ‘amplified’ status of 16 genes were further examined for the respective 
gene amplification by fluorescence in situ hybridization and for the respective 
protein overexpression by immunohistochemistry. The frequencies of gene 
amplifications in advanced gastric cancers were as follows: ERBB2 (13 cases, 
14%), FGFR2 (7 cases, 8%), MYC (7 cases, 8%), TOP2A (7 cases, 8%), MET (4 
cases, 4%), MDM2 (4 cases, 4%), CCND1 (3 cases, 3%), FGF10 (2 cases, 3%), 
and EGFR (one case, 1%). Amplification of the receptor tyrosine kinases genes 
occurred in a mutually exclusive manner except for one tumor in which ERBB2 
and FGFR2 were both amplified but in different cancer cells. Co-amplification of 
ERBB2 and MYC, and EGFR and CCND1, in single nuclei but on different 
amplicons were confirmed in one case each. Attempts at correlating the 
fluorescence in situ hybridization status with the immunohistochemical staining 
pattern showed variable results from complete concordance to no correlation. In 
conclusion, combination of multiple ligation-dependent probe amplification and 
fluorescence in situ hybridization analysis is a feasible approach for obtaining the 
semi-comprehensive genetic information that is necessary for personalized 
molecular targeted therapy.  
 
Abbreviations: fluorescence in situ hybridization (FISH); receptor tyrosine kinase 
(RTK) 
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Gastric cancer is the fourth most common malignancy and ranks second among 
all cancer deaths worldwide.1 According to the Japanese Research Society for 
Gastric Cancer, gastric cancers are divided into two groups: early gastric cancers 
that are confined to the mucosa and submucosa, and advanced gastric cancers that 
penetrate the muscle layer or beyond.2 Estimated proportions of surviving 
Japanese patients with ‘early gastric cancer’ and ‘advanced gastric cancer’ in the 
five-years after surgery are 98.5% and 51.7% respectively.3 Thus, novel 
therapeutic modalities are urgently needed for the treatment of advanced gastric 
carcinomas.  
  In 2009, an open-label, international phase 3, randomized controlled trial 
(ToGA, Trastuzumab for gastric cancer) found that the addition of trastuzumab, a 
humanized monoclonal antibody that binds to the extracellular juxtamembrane 
domain of a receptor tyrosine kinase (RTK), ERBB2, (otherwise known as the 
human epidermal growth factor receptor 2, HER2), to cisplatin-based 
chemotherapy significantly improved the overall survival of advanced gastric 
cancer patients with over-expressed and/or amplified ERBB2 as compared to 
chemotherapy alone.4 To date targeting ERBB2-overexpression/amplification 
remains the only successful and approved targeted therapy for gastric cancer. 
However there is an urgent need for other inhibitors to be investigated for the 
therapy of many of the unique molecular subtypes of gastric cancer.5 In particular, 
FGFR2 and MET, which encode RTKs similar to ERBB2, are considered as strong 
candidate targets because their amplification is associated with advanced stages, 6, 
7 and, furthermore, the amplification of FGFR2 was preferentially found in a 
poorly differentiated subtype.8, 9 In preclinical studies, cells with amplified 
FGFR2 or MET showed overexpression of their respective proteins, and inhibitors 
to these receptors were shown to effectively block their downstream signal 
transduction and induce apoptosis.10-14 Currently, apart from ERBB2 targeting, 
approaches for targeting MET and FGFR2 are the most clinically advanced of 
prospective targeted therapy. However, the prevalence of amplification of each of 
these genes, as assessed by oligonucleotide array comparative genetic 
hybridization, real-time PCR, fluorescence in situ hybridization (FISH), or silver 
in situ hybridization is low: from 2% to 5% for FGFR2,9, 10, 12, 14 and from 2% to 
8% for MET.6, 7, 14, 15 Intriguingly, a recent comprehensive genome-wide analysis 
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of copy number alterations using an single nucleotide polymorphism array 13 
showed that amplification of FGFR2, EGFR, ERBB2, and MET occurred mutually 
exclusively and that other genes such as MYC and CCND1 were also amplified in 
gastric cancer. When considering promising targets of molecular therapy, the 
apparently low prevalence of these gene amplifications in gastric cancer makes 
selection of the right set of patients that can benefit from targeted therapy a 
difficult challenge.  
   Multiplex ligation-dependent probe amplification is a new, high-resolution 
method for detecting numerous copy number variations in genomic sequences in a 
single reaction, and requires only small amounts of DNA extracted from 
formalin-fixed paraffin-embedded tissues.16, 17 This technique makes possible the 
simultaneous detection of the amplification status of ERBB2, EGFR, MET, MYC, 
CCD1 and MDM2. 16 
  The aims of the present study were to determine the gene amplification status 
of RTKs and other cell regulator genes including ERBB2, EGFR, FGFR2, MET, 
MYC, CCND1 and MDM2 in advanced gastric cancers with a view towards future 
introduction of molecular targeted therapy, and to examine the usefulness of 
multiplex ligation-dependent probe amplification in the semi-comprehensive 




Materials and Methods 
 
Patients 
 A total of 93 advanced gastric adenocarcinoma patients out of 262 gastric cancer 
patients who underwent surgery at the Department of Surgery in Kanazawa 
University Hospital between 2011 and 2013 were examined. Cancer staging was 
performed according to the TNM cancer staging system of the American Joint 
Committee of Cancer.18 The World Health Organization Classification of 
Tumors 19 was used to determine histological classification as differentiated 
(tubular adenocarcinoma, papillary adenocarcinoma) or undifferentiated 
adenocarcinoma (mucinous adenocarcinoma, poorly cohesive carcinomas, mixed 
carcinoma, carcinoma with lymphoid stroma and unclassified carcinoma). This 
laboratory study was approved by the Medical Ethics Committee of Kanazawa 
University (Approval No 181), and written informed consent was obtained from 
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all patients. Serial sections cut from representative formalin-fixed and 
paraffin-embedded cancer tissues were used for hematoxylin-eosin staining, 
multiplex ligation-dependent probe amplification, FISH and 
immunohistochemistry. 
 
Multiplex ligation-dependent probe amplification 
  A cancer area was selected on a 6 µm-thick representative tumor section, with 
reference to the adjacent hematoxylin-eosin staining section, taking care that 
non-neoplastic cells were excluded as much as possible. DNA was extracted 
manually from each section using proteinase K (Rosch Diagnostics, Manheim 
Germany) according to the manufacturer’s (MRC-Holland, Amsterdam, The 
Netherlands) protocol. By using this protocol, more than 1 µg of sample DNA 
with an OD260:OD280 ratio within 1.1 -1.7 was obtained from each tumor. DNA 
from the cell lines MKN7, A431, KATOIII, HSC39 and MKN45, which were 
previously shown to display amplified ERBB2, EGFR, FGFR2, FGFR2 and MYC, 
and MET, respectively, were used as positive controls. 8, 20  
Multiplex ligation-dependent probe amplification analysis was performed by 
using two kits from MRC-Holland. The SALSA MLPA KIT P175-A2 Tumor-Gain 
kit contains two or three probes for each of 24 genes including ERBB2, EGFR, 
MET, MYC, CCND1, MDM2 and TOP2A. The SALSA MLPA probemix P231-A2 
FGF10-FGFR2, which was originally used for the diagnosis of autosomal 
dominant lacrimoauriculodentodigital syndrome 21 contains five probes each for 
FGFR2 and FGF10. The PCR products were separated on an ABI-310 capillary 
sequencer (Applied Biosystems, Foster City, CA, USA) and interpreted with 
Genemapper software (Applied Biosystems). Data analysis was performed with 
Coffalyser MLPA-DAT software (version 9.4, MRC-Holland) to generate 
normalized peak values. Average peak values below 0.7 were defined as ‘lost’, 
between 0.7 and 1.3 as ‘normal’, between 1.3 and 2.0 as ‘gain’, and >2.0 as 
‘amplified’, as previously established 16, 17 
 
FISH 
Tumors with ‘amplified’ or ‘gain’ of genes as determined by multiplex 
ligation-dependent probe amplification were further examined using FISH to 
validate the accuracy of the multiplex ligation-dependent probe amplification 
results for the respective gene amplification. FISH probes acquired from 
BACPAC Resources (Oakland, CA) are summarized in Table 1. The probes were 
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labeled with SpectrumOrangeTM or SpectrumGeenTM using a nick translation kit 
(Abbott Laboratories, Abbott Park, IL, USA). For the detection of gene 
amplification, a SpectrumGreenTM-labeled pericentromeric probe (Abbott), 
specific to each chromosome on which the particular gene was located, was 
co-hybridized to standardize the chromosome number. Tumors exhibiting 
co-amplification of different genes were further examined by simultaneous 
hybridization with two probes specific to the genes that were labeled with 
different fluorescent markers to determine the co-existence of the amplified genes 
in single cells and single amplicons. 
Removal of protein from the tissue sections, denaturation, hybridization, and 
post-hybridization washing were performed as described previously.17 The tissue 
sections were counterstained with DAPI II (Abbott) and examined using a 
fluorescence microscope (Olympus, Tokyo, Japan) equipped with a Triple 
Bandpass Filter set (Abbott) for DAPI II, SpectrumOrangeTM and 
SpectrumGreenTM, and a filter set specific for SpectrumOrangeTM or 
SpectrumGreenTM. FISH images were recorded through a cooled charge-coupled 
device camera (DP-70, Olympus) linked to a computer software program (DP 
Manager, Olympus). 
Scoring and evaluation of FISH slide were performed manually by counting 
gene signals and the centromere signals on which the gene was located, of 20 
tumor nuclei per case. The average copy number of the gene and the centromere, 
and their ratio, were determined for each case. Gene amplification was determined 
according to the American Society of Clinical Oncology/College of American 
Pathologists–approved criteria of ERBB2 amplification except that the quantity of 
positive cells was defined as: more than six gene copies per nucleus or gene 
signals/centromere signals >2.2. 22 In addition, low level amplification was 
arbitrarily defined as: gene signals/centromere signals >2.2 and gene copy number 
of less than 6, and high polysomy was arbitrarily defined as: gene 
signals/centromere signals <1.8 and gene copy number greater than 6. In cases of 
apparent intratumoral heterogeneity in gene amplification, the fractions (%) of the 
tumor cells containing gene-amplification were scored using broad tiers of <30%, 
30-70%, and >70%. 
 
Immunohistochemistry 
  Immunohistochemistry for ERBB2, EGFR, FGFR2, MET, MYC, CCND1 and 
MDM2 was performed on tumors with FISH-proved amplification. The antibody 
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clones, manufacturers and dilutions, and the antigen retrieval methods, are 
summarized in Table 2. Antibody binding was visualized using the LSABTM 
system (Dako, Glostrup, Denmark). For evaluation of positive staining of ERBB2, 
EGFR, FGFR2 and MET, each tumor, or portion of tumor, was scored using a 
four-tier system (0, 1+, 2+, 3+) according to the criteria recommended by Dako 
for the HercepTestTM, except that the quantity of positive cells was not considered. 
For evaluation of MYC, CCND1 and MDM staining, only nuclear 
immunostaining that was significantly higher than that of control cells of normal 
gastric mucosa was considered as positive.   
 
Statistical analyses 
The association of gene amplification and histology of the tumor, and association 
between amplifications of different genes were analyzed for significance using 







Multiplex ligation-dependent probe amplification 
  Multiplex ligation-dependent probe amplification analyses were successfully 
performed on all 93 of the formalin-fixed and paraffin-embedded advanced gastric 
adenocarcinoma tissue samples. The gene status of the 26 genes analyzed in the 
93 tumors were categorized as ‘amplified’, ‘gain’, or ‘normal’ based on the mean 
multiplex ligation-dependent probe amplification peak values. There were no 
cases with ‘lost’ genes. The number of tumors with ‘amplified’ or ‘gain’ of 
specific genes by multiplex ligation-dependent probe amplification analysis is 
summarized in Table 1. All tumors displayed a normal copy number of MYCN, 




  Out of the total 93 advanced gastric cancers, 32 tumors (34%) displayed 
gene amplification of one of FGFR10, EGFR, MET, MYC, FGFR2, CCND1, 
MDM2, ERBB2 or TOP2A. In FISH analysis, most amplifications appeared as 
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either tightly clustered or numerous scattered signals of the amplified genes 
suggesting amplicons in homogeneously staining regions and double minute 
chromosomes respectively.23 Cancer nuclei with co-localization of an amplified 
gene and the amplified centromeric lesion on which the gene is located, which 
results in a yellow fusion signal 24 as shown in Suppl. Fig. 1, was rarely observed. 
Approximately half of the gene amplifications occurred in an intratumoral 
heterogeneous fashion.  
  All tumors with genes that were categorized as ‘amplified’ by multiplex 
ligation-dependent probe amplification had cancer cells with gene amplification 
that could be detected by FISH as shown in Table 1.  The tumors with ‘gain’ of 
MDM2, SMO, BRAF, FGFR1, CDK4, AURKA and AR by multiplex 
ligation-dependent probe amplification showed polysomy of the chromosome on 
which the target gene is located; however amplification of these genes was not 
found. 
  Table 3 describes the clinicopathological characteristics of the 32 tumors 
with gene amplification and indicates the fraction (%) of the amplified cells and 
the type of amplification in each case. Three quarters (24 of 32) of the 
amplifications were of genes encoding RTKs: representative FISH images of 
amplified ERBB2, FGFR2, MET and EGFR were shown in Figs 1A and B, 1A and 
2A, 3A and 3C, and 4A respectively. Except for Case 7, amplification of these 
RTK genes occurred in a mutually exclusively manner i.e. each tumor had a single 
RTK gene mutation. In Case 7, dual color FISH analysis demonstrated 
‘homogeneously staining region’-type ERBB2 amplification and ‘double minute 
chromosome’-type FGFR2 amplification intermingled in a mosaic pattern. 
However, no single cell had amplification of both genes, as shown by dual color 
FISH in Fig. 1A. MYC was amplified in seven tumors, and was co-amplified with 
ERBB2 in three tumors. Based on dual-color FISH analysis, co-amplification of 
ERBB2 and MYC in single nuclei but on different amplicons was confirmed in 
case 9 (Fig. 1B). MDM2 amplification was found in 4 tumors; one showed 
co-amplification with ERBB2 and the other showed co-amplification with the 
FGFR2, however cancer cells with different gene amplification occupied different 
tumor areas as shown in Fig 2. CCND1 was amplified in three tumors; one 
showed co-amplification with EGFR and the other with FGFR2. Dual-color FISH 
analysis could confirm co-amplification of EGFR and CCND1 in single nuclei but 
on different amplicons in case 24 (Fig. 4A). All of the tumors with TOP2A 
amplification were also positive for ERBB2-amplification. Furthermore, 
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dual-color FISH showed that TOP2A signals and ERBB2 signals were closely 
associated (Suppl. Fig. 2).  
 
Immunohistochemistry 
  Immunohistochemistry for ERBB2, indicated 11 tumors with 3+ or 2+ staining 
(Fig. 1E), one tumor with 1+ staining (Case 7) (Fig. 1C) and one tumor (case 10) 
was negative. Immunohistochemistry for FGFR2 displayed a variety of 
cytoplasmic staining from weak to strong, which was found to correspond to 
FGFR2 amplified tumor cells (Fig 1D and 2D). However similar cytoplasmic 
staining was also commonly found in non-FGFR2-amplified cancer cells (Figs. 
2A, B and D) and occasionally in non-neoplastic glandular cells. 
Immunohistochemistry of MET showed inconsistent results; 3+ staining in Case 
21 (Fig. 3B), 2+ staining in Cases 22 and 23, and negative staining in Case 20. In 
Case 21 the MET amplification-positive and -negative cells were randomly 
intermingled; even single cancer tubules were composed of amplification-positive 
and -negative cells. FISH analysis of serial sections showed that the MET 
amplified cells corresponded to MET 3+ immunostained cells, and that non-MET 
amplified cells corresponded to MET immunohistochemically-negative cells as 
shown in Figs. 3A and B. In Case 22, MET-amplified and non-amplified cells 
were in different areas and both showed 2+ MET immunostaining. Thus these 
cells were not differentiated by immunohistochemistry as shown in Figs. 3E and F. 
Case 24 that showed homogeneous EGFR amplification showed 
3+ immunostaining of the EGFR (Fig.4B). 
    Most immunohistochemical results of MYC were equivocal (Fig. 1F). In the 
immunohistochemistry analysis of MDM2 and CCND1, scattered positive nuclear 
staining was found and clear coincidence of this staining with the respective 




Amplification of ERBB2 was significantly more frequent in differentiated 
carcinomas than in undifferentiated carcinomas (p=0.04), however the 




9 / 20 
 




  In the present study 32 of a total of 93 advanced gastric cancers (34%) 
displayed definite gene amplification and most of this amplification occurred in a 
FISH pattern that was reminiscent of cytogenetic homogeneously staining region 
or double minute chromosomes. Furthermore 26% (24 of 93) of the amplifications 
were amplification of one of four genes (ERBB2, FGFR2, MET and EGFR) that 
encode a RTK. The frequencies of these gene amplifications were not 
significantly different from those previously reported for ERBB2, FGFR2, 12 9, 10, 
14 MET 6, 7, 14, 15 and the EGFR. 6, 20 It is intriguing that, except for case 7, RTK 
gene amplification occurred in a mutually exclusive manner. Even in Case 7, RTK 
gene co-amplification did not occur in the same cells. Thus if a common tyrosine 
kinase inhibitor to the four RTKs were available, 24 of 93 (26%) cases of 
advanced gastric cancer would potentially be susceptible to that agent. This 
characteristic of RTKs is one of the reasons why RTK gene amplifications have 
attracted much attention as molecular targets even though the prevalence of 
individual RTK gene amplification is low. 6, 12, 13  
  However, if small fractions of amplified cells that cannot be detect by screening 
with multiplex ligation-dependent probe amplification and/or early gastric cancers 
are included, co-amplification of RTK genes is not exceptional in gastric cancers. 
On the contrary, our previous study showed a marginal trend for co-amplification 
of EGFR and ERBB2; however, this trend was not statistically significant.25 In our 
more recent study in which we examined the co-amplification of ERBB2 and other 
RTK genes, we found that of 51 tumors with ERBB2-amplification, 14% (7/51) of 
the tumors displayed co-amplification with EGFR, one tumor showed 
co-amplification with FGFR2, and one tumor showed co-amplification with MET 
and FGFR2.16 It is probable that redundancy of RTKs, which are unnecessary for 
cancer cell growth, diminishes in the course of gastric cancer progression.  
  In contrast to the lack of co-amplification of RTK genes, MYC and RTK genes 
are occasionally co-amplified in single cancer cells. In the present study 
co-amplification of MYC and ERBB2 in the same cell was found in three tumors, 
and, in our previous study, co-amplification of MYC and ERBB2 or EGFR occurs 
in a non-incidental manner.25 Thus these co-amplifications may be of some merit 
for survival of cancer cells. A similar selective co-amplification of ERBB2 and 
MYC was found in breast cancer cells and it has been speculated that this 
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co-amplification might be a very favorable prognostic factor when combined with 
adjuvant therapy by trastuzumab.26, 27 However, this hypothesis was recently 
refuted. Instead new data have shown that this co-amplification is associated with 
poor outcome and is associated with the sequence of acquisition of a malignant 
stem cell-like phenotype that maintains lower growth and therefore may be a key 
target of new therapy. 28 
  TOP2A resides very close to ERBB2 on the chromosome and its amplification 
was only observed with the concomitant amplification of ERBB2. However 
TOP2A is not simply a ‘passenger’ gene because TOP2A encodes an enzyme, 
topoisomerase IIα, that is required for DNA replication. Moreover, clinical 
studies have confirmed that breast cancer patients with TOP2A gene amplification 
are more sensitive to topoisomerase IIα-based therapy.29 Unfortunately this 
therapy is not commonly used for the treatment of gastric cancers in Japan.  
  Information regarding CCND1 amplification is useful because expression of 
CCND1 may cause resistance to cisplatin,30 which was co-administered with 
trastuzumab in the ToGA clinical trial. To the best of my knowledge, this is the 
first report of amplification of FGF10 in gastric cancer. Although stomach 
development is dependent on FGF10 and FGFR2 mediated signaling,31 it remains 
to be clarified whether FGF10 amplification is relevant to carcinogenesis of 
gastric cancer through enhanced signaling. In this study an additional candidate 
for molecular targeting, amplified MDM2, was found in ERBB2-non-amplified 
gastric cancers. MDM2, is an oncogene whose expression controls tumorigenesis 
by promoting degradation of the tumor suppressor protein p53. Amplification of 
MDM2 impacts cancer treatments that use selective inhibitors of MDM2 
proteins. 3 2 ,  3 3 Indeed, in an in vivo study, treatment with nutlin, an MDM2 
antagonist, induced p53-dependent transcription and apoptosis in liposarcoma 
cells that were positive for MDM2 amplification. 34 
In this study we screened advanced gastric carcinomas for possible gene 
amplification by multiplex ligation-dependent probe amplification and confirmed 
the results obtained using FISH analysis, which has been considered as the gold 
standard method for analysis of gene amplification. FISH probes span 
approximately 200 kb of DNA sequence, which is similar to, or several-fold larger 
than the target gene size. In contrast, multiplex ligation-dependent probe 
amplification targets intragenic portions of DNA sequence with sequence sizes of 
50-100 bases. Although for a typical gene amplification the result of multiplex 
ligation-dependent probe amplification should theoretically coincide with that of 
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FISH, the copy number detected by multiplex ligation-dependent probe 
amplification was often lower than that detected by FISH due to intratumoral 
heterogeneity and/or contamination of non-neoplastic DNA. In the present study, 
the cut-off value of 1.3 that was recommended by the multiplex 
ligation-dependent probe amplification kit manufacturer was used for all of the 
genes. Although all of the cases defined as ‘amplified’ by multiplex 
ligation-dependent probe amplification were also amplified by FISH analysis, 
seven genes that were defined as ‘gain’ by multiplex ligation-dependent probe 
amplification showed no real amplification by FISH analysis (Table 1). It may 
therefore be possible to increase the specificity of the test by resetting the cut-off 
values for these genes.35 However, for the purpose of screening of gene 
amplification, high sensitivity precedes specificity and the cut-off value of 1.3 was 
very acceptable for such screening. 
MYC, CCND1, MDM2, ERBB2, EGFR, FGFR2 and MET are considered to 
be involved in carcinogenesis through protein overexpression of amplified genes. 
Thus immunohistochemistry that is familiar to most diagnostic pathologists might 
be the first choice for examination of these aberrations. However, our attempts to 
correlate FISH status with immunohistochemical staining resulted in variable 
correlations between the two types of measurement ranging from complete 
correspondence to dissociation. The protein overexpression of MYC, CCND1 and 
MDM2 is regulated by several pathways and thus gene amplification may not 
necessarily provide a straightforward correlation with protein overexpression. As 
for RTK genes, the hypothesis that ‘amplification causes overexpression’ is 
fundamentally established for ERBB2, and is highly supported for EGFR, FGFR2, 
and MET. 10-14. However, even for RTKs, inconsistent results between FISH and 
immunohistochemical analyses were often obtained, due mostly to inherent 
technical reasons of immunohistochemistry such as specificity of antibodies, 
fixative used, duration of fixation, staining procedures, and/or scoring system. 
Therefore, at the present time gene amplification provides the best biomarkers for 
helping to select the right patient candidate for molecular therapy targeted towards 
these genes, and multiplex ligation-dependent probe amplification is the most 
feasible method for screening these gene amplifications.  
  In conclusion given the apparent low prevalence of amplification of candidate 
target oncogenes for therapy of gastric cancer, implementation of 
semi-comprehensive screening by multiplex ligation-dependent probe 
amplification followed by confirmatory FISH analysis, should facilitate the 
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identification of patients who may benefit from such tailored therapy. 
 





Genes with increased copy number (‘amplified’ or ‘gain’) detected by multiplex 
ligation-dependent probe amplification in advanced gastric cancer. Values in 
parentheses are the numbers of tumors with gene amplification detected by FISH. 
 
Table 2. 
Antibodies and dilutions applied for immunohistochemistry. 
Abbreviations: MW, microwave; PC, pressure cooking 
 
Table 3. 
Advanced gastric cancers with gene amplification. Numbers in parentheses 
indicate % of the amplified cells in each case. 
Abbreviations: tub, tubular adenocarcinoma; por, poorly cohesive 
adenocarcinoma; pap, papillary adenocarcinoma; mixed, mixed carcinoma; muc, 
mucinous carcinoma; DCS, combination chemotherapy with docetaxcel, cisplatin 
and S-1; DOC, docetaxcel; HSR, homogeneously staining region type 
amplification; DM, double minute chromosome type amplification; co-amp HSR, 
co-amplification of a gene and the centromeric lesion in HSR; high poly, high 
polysomy; low amp, low amplification.  
 
Fig. 1 
Gastric cancers with co-amplification of ERBB2 and FGFR2 (Case 7), and ERBB2 
and MYC (Case 9). In Case 7 amplification of ERBB2 and FGFR2 was found in 
different cancer cells. In Case 9 ERBB2 and MYC was in the same nuclei. Gene 
amplifications were analyzed by dual-color FISH (A: green fluorescence, ERBB2; 
orange fluorescence, FGFR2) (B: green fluorescence, ERBB2; orange 
fluorescence, MYC), and their protein overexpression was analyzed 
by immunohistochemistry (C and E, ERBB2; D, FGFR2; F, MYC). Panels A, C 
and D show the same field. ERBB2- and FGFR2-amplified cells in Panel A 
correspond to the 1+ ERBB2 stained cells in Panel C and the cells with weak 
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cytoplasmic staining of FGFR2 in panel D, respectively. The cells with gene 
amplification in Panel B showed 2+ immunostaining of ERBB2 and equivocal 




A poorly cohesive type gastric cancer with FGFR2-amplified and 
MDM2-amplified cancer cells in different areas (Case 17). FGFR2 and MDM2 
gene amplification was analyzed by dual-color FISH (A and B: orange 
fluorescence, FGFR2; green fluorescence, centromere 10. C: orange fluorescence, 
MDM2; green fluorescence, centromere 12) and their protein overexpression was 
analyzed by immunohistochemistry (D, FGFR2; E, MDM2). Panels A and B are 
different fields of the same area of panel D. Intense cytoplasmic staining of 
FGFR2 (D) was detected in both FGFR2-amplified (A) and 
FGFR2-non-amplified (B) cells. Panels C and E are the same area. Most but not 
all MDM2-amplified cells show 3+-nuclear staining of MDM2.  
 
Fig. 3 
Amplification and overexpression of MET in gastric carcinomas (Cases 21 and 
22). A tubular adenocarcinoma (Case 21, A and B) and a poorly cohesive type 
adenocarcinoma (Case 22, C-F) were analyzed for MET gene amplification by 
dual-color FISH (A, C and D: orange signals, MET; green signals, centromere 7) 
and for MET protein overexpression by immunohistochemistry (B, E and F). In 
the tubular adenocarcinoma (Case 21), cancer cells with 3+-immunostaining of 
MET displayed amplified MET; cells with negative immmunostaining displayed 
no amplification (A and B). The region enclosed by the black rectangle in panel B 
corresponds to the region shown in panel A. The poorly cohesive type 
adenocarcinoma (Case 22) consisted of MET-amplified (C) and non-amplified 
cancer cells (D) in different areas and both areas displayed 2+-staining for MET 
by immunohistochemistry (E and F). Panels C and E, and panels D and F are the 
same field.  
 
Fig. 4 
A gastric cancer with co-amplification of EGFR and CCND1 in the same nuclei 
(Case 24). EGFR and CCND1 gene amplification was analyzed by dual-color 
FISH (A: green fluorescence, EGFR; orange fluorescence, CCND1), and their 
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protein overexpression was analyzed by immunohistochemistry (B, EGFR; C, 
CCND1). The gene amplified cells showed 3+-immunostaining of the EGFR and 




Suppl. Fig. 1  
Example of cancer nuclei with rare co-localization of an amplified gene and the 
amplified centromeric lesion on which the gene is located (Case 9). Dual-color 
FISH showed tumor cells with co-localization of amplified ERBB2 (orange) and 
the corresponding amplified centromeric 17 lesion on which it is located (green). 
Large yellow signals overlap orange and green signals. The same field was 
observed using a tripleband filter (A), a SpectrumOrangeTM-specific filter (B) and 
a SpectrumGreen TM -specific filter (C). 
 
Suppl. Fig. 2 
Co-amplification of TOP2A and ERBB2 in gastric cancer (Case 12). 
Dual-color FISH analysis of ERBB2 (green fluorescence) and TOP2A (orange 
fluorescence). This analysis showed that both signals are clustered and that these 
signals overlap. The same field was observed using the tripleband filter (A), 
SpectrumOrangeTM-specific filter (B) and SpectrumGreen TM -specific filter (C). 
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Name of gene MDM4 FGF10 EGFR MET SMO BRAF FGFR1 MYC FGFR2 CCND1 CDK4 MDM2 ERBB2 TOP2A AURKA AR
Chromosomal locus of gen 1q32.1 5p13 7p11.2 7q31.2 7q32.3 7q34 8p11.23 8q24.13 10q26 11q13.3 12q14.1 12q15 17q12 17q21.2 20q13.31 Xq12
FISH probe RP11-430C7 RP11-273G19 RP11-339F13 RP11-75I20 RP11-152K21 RP11-1065D4 RP11-148D21 RP11-440N18 RP11-62L18 RP11-300I6 RP11-571M6 RP11-775J10 RP11-62N23 RP11-480O10 RP11-75K20 RP11-80F19
No. of 'Amplified' tumors 0 2 (2) 1 (1) 1 (1) 0 0 0 3 (3) 4 (4) 3 (3) 0 1 (1) 11 (11) 4 (4) 0 0
No. of 'Gain' tumors 8 (0) 5 (1) 5 (0) 4 (3) 2 (0) 16 (0) 2 (0) 10 (6) 10 (5) 0 (0) 2 (0) 19 (3) 5 (3) 13 (4) 15 (0) 21 (0)
Values in parentheses are the numbers of tumors with gene amplification detected by FISH
Antibody Clone Dilution Antigen retreval Manufacturer
ERBB2 polyclonal 1:400 None Nichirei, Tokyo, Japan
EGFR EGFR.25 1:100 PC pH6, Citrate Novocastra Lab, Newcastle, UK
FGFR2 ab58201 1:1000 None Abcam, Cambridge, UK
MYC Y69 1:50 PC pH9, EDTA Pharmingen, San Diego, CA, USA
MDM2 IF2 1:40 PC pH6, Citrate Calbiochem, La Jolla, CA, USA
MET SP44 1:50 PC pH6, Citrate Spring Bioscience, Pleeasanton, CA, USA
CCND1 SP4 Prediluted PC pH6, Citrate Nichirei, Tokyo, Japan
Case Histological Anatomic stage / Neoajduvant
 No. classification Prognostic groups therapy ERBB2 TOP2A FGFR2 MET EGFR MYC MDM2 CCND1 FGF10
1 tub IV HSR  (>70)
2 tub IV DCS HSR  (>70) HSR  (>70)
3 por IV DCS/Herceptin DM   (>70)
4 tub IV Low amp   (30-70) HSR (30-70)
5 tub IV HSR   (>70) Low amp  (>70)
6 tub IV DCS HSR  (>70) Low amp  (>70)
7 tub IIIC DCS HSR　(30-70) DM (30-70)
8 tub IIIB DCS ＤＭ　 (>70) DM (30-70)
9 tub IIIB S-1 co-amp HSR  (>70) co-amp HSR  (>70) High poly  (>70) Low amp (>70)
10 tub IIIA low amp  (>70) Low amp  (>70)
11 tub IIIA HSR  (>70) HSR (>70)
12 tub IIA co-amp HSR  (>70) co-amp HSR  (>70)  HSR  (>70)
13 tub IIA HSR (30-70)
14 por IV DM (30-70)
15 por IV High poly (30-70) HSR (30-70)
16 por IIIB DCS DM (30-70)
17 por IIIA DM (<30) DM (<30)
18 por IIA HSR (>70)
19 tub IIA DM (30-70)
20 por IV DCS Low amp   (>70)
21 tub IV DCS DM  (30-70)
22 por IV DCS HSR  (30-70)
23 muc IIIA HSR (30-70)
24 tub IIIA  DM  (>70) HSR (>70)
25 por IV DCS HSR  (>70)
26 por IV DM>>HSR (30-70) HSR  (>70)
27 por IIIB S-1/DOC DM  (30-70)
28 pap IIB HSR (30-70)
29 por IIIA DCS Low amp> DM (>70)
30 tub IV Low amp  (>70)
31 por IIA DCS DM (30-70)
32 mixed IIIA DCS Low amp (>70)
13 7 7 4 1 7 4 3 2
14 8 8 4 1 8 4 3 3
Numbers of cases with gene amplification 
Fraction (%) of cases with gene amplification
FISH findings of amplified genes
